An interventional study of BAO-G in Thoracoabdominal Aortic Aneurysm, Endovascular Repair and Complex Aortic Aneurysms, sponsored by Peking Union Medical College Hospital. Recruiting at 11 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Multi-Branch AOrtic Reconstruction With G-iliac System (BAO-G) Technique is a novel technique of endovascular repair of complex aortic aneurysm, which using off-the-shelf iliac branched devices to reconstruct the visceral branches. This study aims to verify the perioperative safety and 5-year efficacy of BAO-G technique in the endovascular treatment of complex aortic aneurysms through a prospective, multicenter, open-label, single-arm clinical trial, and to provide evidence for the selection of clinical procedures for complex aortic aneurysm patients in the future.
63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.
This study's planned enrollment of 60 is below the median of 80 across 41 interventional studies indexed under Aortic Aneurysm, Thoracoabdominal.
Browse Aortic Aneurysm, Thoracoabdominal studies →Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: BAO-G
Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.
Incidence of primary technical success
The preoperative planned protocol was successfully completed, including aneurysm repair and visceral branch reconstruction, with no aneurysm-related conversion to open surgery/death, no type I/III endoleak, and no branch occlusion within 30 days postoperatively.
Time frame: within 30 days postoperatively
Incidence of clinical success
The preoperative planned protocol was successfully completed, including aneurysm repair and visceral branch reconstruction, without significant disabling permanent clinical sequelae, and with the patient remained free from aneurysm-related mortality or secondary interventions due to aneurysm progression during follow-up.
Time frame: within 5 years postoperatively
Incidence of aneurysm-related death occurred during perioperative period
All deaths occurring before discharge or within 30 days postoperatively that were attributable to the surgical treatment (including stent-induced retrograde dissection, procedure-related aneurysm rupture, branch occlusion causing severe visceral ischemia, etc.) or aneurysm progression, unless there is clear evidence demonstrating the patient's death was unrelated to the aneurysm.
Time frame: within 30 days postoperatively
Incidence of rupture of aneurysms
Time frame: within 5 years postoperatively
Incidence of permanent paraplegia
Time frame: within 5 years postoperatively
Incidence of permanent lower limb monoparesis
Time frame: within 5 years postoperatively
Incidence of new-onset dialysis-dependent renal failure
Time frame: within 5 years postoperatively
Incidence of severe bowel ischemia
Time frame: within 5 years postoperatively
Incidence of disabling stroke
Time frame: within 5 years postoperatively
Intraoperative blood loss
Time frame: during the operation
Incidence of vascular access complications
Time frame: within 5 years postoperatively
Operative time
Time frame: during the operation
Length of stay (LOS)
Time frame: From the date of hospital admission until the date of hospital discharge, assessed up to 5 years
Length of stay for planned staged procedures
Time frame: From the date of hospital admission until the date of hospital discharge, assessed up to 5 years
Incidence of adjunctive primary technical success
Required unplanned additional endovascular techniques (e.g., parallel stent-graft technique) to achieve aneurysm exclusion, without type I/III endoleak and with branch patency for 30 days
Time frame: within 30 days postoperatively
Incidence of secondary technical success
Required unplanned surgical conversion to complete aneurysm exclusion, without type I/III endoleak and with branch patency for 30 days.
Time frame: within 30 days postoperatively
Incidence of stent migration
Definitive stent migration (≥10mm axial displacement) confirmed by evaluation using anatomical landmarks on the first postoperative CT.
Time frame: within 5 years postoperatively
Incidence of aneurysm enlargement
Aneurysm enlargement (\>5mm maximum diameter increase) demonstrated on perioperative and follow-up CTA.
Time frame: within 5 years postoperatively
Incidence of significant distal embolization
Stent-induced lower limb arterial embolism with ischemia requiring surgical intervention, amputation, or resulting in death.
Time frame: within 5 years postoperatively
Incidence of Stent- or procedure-related exploratory laparotomy
Adverse event requiring exploratory laparotomy due to stent- or procedure-related complications
Time frame: within 5 years postoperatively
Incidence of aortoiliac stent occlusion
Occlusion of aortic branch stents, iliac branch devices, or iliac limb extensions
Time frame: within 5 years postoperatively
Rate of primary stent patency
Patency of branch stents and bridging stents, with no in-stent restenosis or occlusion.
Time frame: within 5 years postoperatively
Rate of adjunctive primary stent patency
Secondary intervention was required due to branch/bridging stent kinking or in-stent restenosis, with patency restored after the additional procedure.
Time frame: within 5 years postoperatively
Rate of secondary stent patency
Patency restored after secondary intervention for branch/bridging stent occlusion.
Time frame: within 5 years postoperatively
Incidence of reoperation
Unplanned reoperation related to stent or procedure within the intended treatment zone, excluding access-related reinterventions and procedures outside the target anatomical area.
Time frame: within 5 years postoperatively
Incidence of acute kidney injury
A perioperative increase in serum creatinine to 1.5-2 times the preoperative baseline value according to RIFLE criteria.
Time frame: within 30 days postoperatively
Incidence of Type I endoleak
Endoleak originating from proximal or distal seal zones
Time frame: within 5 years postoperatively
Incidence of Type Ia endoleak
Endoleak originating from the proximal seal zone of aortic stent
Time frame: within 5 years postoperatively
Incidence of Type Ib endoleak
Endoleak originating from the distal seal zone of aortic or iliac stents
Time frame: within 5 years postoperatively
Incidence of Type Ic endoleak
Endoleak originating from the distal seal zone of visceral artery stents
Time frame: within 5 years postoperatively
Incidence of Type II endoleak
Endoleak originating from aortic branches (e.g., inferior mesenteric artery, lumbar arteries, intercostal arteries)
Time frame: within 5 years postoperatively
Incidence of Type III endoleak
Endoleak originating from stent junctions or device structural failure
Time frame: within 5 years postoperatively
Incidence of Type IIIa endoleak
Endoleak due to aortoiliac stent junctional failure
Time frame: within 5 years postoperatively
Incidence of Type IIIb endoleak
Endoleak caused by fracture or disruption of visceral artery stents within branch vessels
Time frame: within 5 years postoperatively
Incidence of Type IIIc endoleak
Endoleak into the aortic aneurysm sac due to poor connection or structural failure between visceral branch bridging stents and aortic branch stents
Time frame: within 5 years postoperatively
Incidence of Type IV endoleak
Endoleak due to stent-graft fabric permeability
Time frame: within 5 years postoperatively
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2022 (actual). Primary completion is estimated for Dec 2030, 107 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aortic Aneurysm, Thoracoabdominal →
Peking Union Medical College Hospital →